by Jenni Ho, University of Kentucky Fig 1. Ovarian cancer cell lines exhibit varied responses to paclitaxel treatment. Paclitaxel-resistant (PacR) and parental control ovarian cancer cell lines, TOV-21G and OVCAR3, were treated with serially diluted doses of paclitaxel for 96 hours in vitro. Cell viability is displayed at each concentration tested relative to untreated cells for...
by Netherlands Cancer Institute Credit: CC0 Public Domain Liver cancer is one of the most common cancer types worldwide and is especially common in China. A collaborative effort between researchers at the Netherlands Cancer Institute and Shanghai using CRISPR/Cas has led to the discovery that insensitivity to a liver cancer drug can be prevented if it is given...
UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson Cancer Center. Findings from the single-institution Phase II study were published today in JAMA Oncology and provide the longest...
by McGill University Credit: McGill University Breast cancer is the leading cause of cancer death in women around the world, responsible for 1,700 deaths every day. Although the vast majority of breast cancers are treatable, the most aggressive subtype—triple negative breast cancer (TNBC) – has a high recurrence rate, a high potential for metastasis, and shows...
